30 closest matches · ranked by relevance
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Progression-free Survival — 11.8 Months
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Rate of Complete Response — 38; 7; 11 Participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Extragonadal Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment — 3; 7 participants
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Extragonadal Germ Cell Tumor · Teratoma · Testicular Germ Cell Tumor
Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
CNS Lymphoma · CNS Brain Cancer · Non-Hodgkin's Lymphoma
Primary: Number of Participants Evaluated for Toxicity — 33 Participants
Recurrent Childhood Anaplastic Astrocytoma · Recurrent Childhood Brain Stem Glioma · Recurrent Childhood Ependymoma
Primary: Relative Phosphorylation of ERBB2 (Molecular Biology Objective) — .21; .50 ratio
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Response — 12; 6; 5 participants
Glioblastoma Multiforme
Primary: Number of Participants With Local Recurrence in the Spared NPC Niches — 0 Participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities